LogicBio Therapeutics (OTCMKTS:LOGC) Stock Price Up 0.8% – What’s Next?

by · The Markets Daily

LogicBio Therapeutics, Inc. (OTCMKTS:LOGC – Get Free Report) shares were up 0.8% during mid-day trading on Monday . The stock traded as high as $9.15 and last traded at $9.05. Approximately 79,971 shares changed hands during trading, a decline of 23% from the average daily volume of 104,232 shares. The stock had previously closed at $8.98.

Analyst Ratings Changes

Separately, Wall Street Zen cut shares of LogicBio Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, March 29th.

Read Our Latest Stock Analysis on LOGC

LogicBio Therapeutics Stock Performance

The firm has a market capitalization of $413.86 million, a price-to-earnings ratio of -8.30 and a beta of 2.09. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.67 and a quick ratio of 1.15. The firm has a 50 day moving average price of $8.50 and a 200-day moving average price of $8.04.

Institutional Trading of LogicBio Therapeutics

An institutional investor recently raised its position in LogicBio Therapeutics stock. Goldman Sachs Group Inc. boosted its position in LogicBio Therapeutics, Inc. (OTCMKTS:LOGC – Free Report) by 284.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 526,673 shares of the company’s stock after acquiring an additional 389,843 shares during the quarter. Goldman Sachs Group Inc. owned 2.00% of LogicBio Therapeutics worth $3,676,000 at the end of the most recent quarter. Institutional investors and hedge funds own 46.05% of the company’s stock.

LogicBio Therapeutics Company Profile

(Get Free Report)

LogicBio Therapeutics, Inc, a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia.

Further Reading